Investor Confidence Wavers as ProMIS Neurosciences Unveils New Equity Strategy

ProMIS Neurosciences shares fell over 13% after announcing a $50M ATM equity offering, raising dilution fears despite solid funding into 2027 and progress in its Alzheimer's trial.

ProMIS Neurosciences continues to advance the clinical development of its Alzheimer's drug candidate, PMN310, yet the substantial costs associated with this research have brought financial sustainability into focus. The company's recent move to establish a flexible capital-raising mechanism has unsettled the market, contributing to a significant decline in its share price despite reported progress in its core programs.

Shareholder Dilution Fears Trigger Sell-Off

Market sentiment turned negative following ProMIS's announcement that it has initiated an At-the-Market (ATM) equity offering program. This facility grants the company the ability to issue and sell up to $50 million worth of its common shares directly into the trading market at its discretion. While such arrangements provide biotechnology firms with a crucial liquidity safety net, they frequently prompt investor concerns over the potential dilution of existing shareholdings. The reaction was swift: shares plummeted more than 13% in a single trading session, hitting a new 52-week low of €12.80.

The company's current financial runway, however, is not immediately precarious. A private placement completed in February 2026 raised approximately $75.5 million. Management indicates that, when combined with existing capital reserves, these funds are projected to support ongoing clinical operations through 2027. For the 2025 fiscal year, ProMIS reported a net loss of $39.7 million.

Clinical Advancements Amid Financial Headwinds

On the operational front, ProMIS has achieved key milestones for its lead therapeutic candidate. Patient enrollment for the Phase 1b "PRECISE-AD" clinical trial was successfully concluded in December, surpassing initial targets with 144 participants. The investigational antibody, PMN310, is designed to selectively target toxic amyloid-beta oligomers and has so far demonstrated a favorable safety profile with no serious adverse events noted.

Attention now shifts to upcoming clinical data readouts. The six-month patient assessments from the study are scheduled for completion in the second quarter of 2026. An initial blinded interim analysis is anticipated at the start of Q3 2026, with the final twelve-month study results expected in early 2027.